Evaluation of array comparative genomic hybridization in recurrent miscarriage.
- [Show abstract] [Hide abstract]
ABSTRACT: The authors report a case of a 61-year-old woman diagnosed with large bladder diverticulum. Diagnosis was performed only after a series of investigations carried out for the occasional finding of hypercreatininaemia. Although the significant volumes of post void residual (PVR) and the relevant urine stagnation in the diverticulum, subjective symptomatology was absent and urinalysis and urine culture were negative. The scheduled therapeutic plan consisted of fosfomycin three grams every ten days for sixmonths, self-catheterization twice a day, voiding on a time schedule, and adequate fluid intake. The monthly scheduled follow-up at one year showed good general health, good compliance with the therapy, no urinary tract infections, a decrease in creatininemia to 1.2 mg/dl, and regression of nephrohydrosis to a mild stage. In conclusion, the absence of symptoms and negative urinalysis or urine culture allows expectant management despite the considerable size of the bladder diverticulum.Clinical and experimental obstetrics & gynecology 01/2014; 41(1):87-9. · 0.36 Impact Factor
- BMC Genomics 01/2014; 15(Suppl 2):P73. DOI:10.1186/1471-2164-15-S2-P73 · 4.04 Impact Factor
Article: Mid-Trimester Pregnancy Loss.[Show abstract] [Hide abstract]
ABSTRACT: Mid-trimester pregnancy loss (MTL) occurs between 12 and 24 weeks' gestation. The true incidence of this pregnancy complication is unknown, because research into MTL in isolation is scarce, although the estimated incidence has been noted to be 2% to 3% of pregnancies. A comprehensive preconceptual screening protocol is recommended, because the cause for an MTL may be present in isolation or combined (dual pathology), and is often heterogeneous. Patients with a history of MTL are at an increased risk of future miscarriage and preterm delivery. This risk is increased further depending on the number of associative factors diagnosed.Obstetrics and Gynecology Clinics of North America 03/2014; 41(1):87-102. DOI:10.1016/j.ogc.2013.10.007 · 1.40 Impact Factor